글로벌 트라코마 시장 – 2029년까지의 산업 동향 및 예측

시장 분석 및 규모

최근 몇 년 동안 트라코마 시장은 예측 기간 동안 빠르게 성장할 것으로 예상됩니다. 트라코마는 클라미디아 트라코마티스 박테리아에 의해 발생하는 전염성 눈 질환이며, 세계보건기구(WHO)에 따르면 실명의 가장 큰 원인이며 세계에서 가장 가난한 10억 명의 사람들에게 영향을 미치는 20가지 소홀히 여겨지는 열대성 질병 중 하나입니다. 또한 세계보건기구(2018)에 따르면 약 8,910만 명이 트라코마를 없애는 약으로 치료를 받았으며, 이로 인해 시장 수익 성장이 촉진되었습니다.

Data Bridge Market Research는 트라코마 시장이 2021년에 5억 1,466만 달러 규모였으며 2029년까지 7억 8,984만 달러에 도달할 것으로 예상하고 2022년부터 2029년까지의 예측 기간 동안 5.50%의 CAGR을 기록할 것으로 분석했습니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

시장 정의

트라코마는 눈 표면에 영향을 미치는 박테리아 감염으로 매우 전염성이 강합니다. 흉터 조직이나 궤양이 시간이 지남에 따라 쌓여 실명으로 이어질 수 있습니다. 감염된 사람의 눈 분비물에 있는 박테리아가 사람과 사람의 접촉이나 특히 Musca sorbens 파리와 같은 눈을 찾는 파리를 통해 다른 사람에게 옮겨갈 때 퍼집니다. 위생 시설과 깨끗한 물이 부족한 풍토병 인구에서 특히 흔합니다.

보고 범위 및 시장 세분화

Trachoma Market Dynamics

Drivers

• Increasing prevalence of trachoma

The rising prevalence of trachoma is a primary driver of the trachoma market's growth. As per the World Health Organization (WHO), 157.7 million people are suffering from trachoma across the globe and approximately 2 million people have become blind.   

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of trachoma market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the trachoma market. Additionally, high disposable income and favorable government initiatives will result in the expansion of trachoma market. Along with this, rising incidences of eye infection and poor sanitation will enhance the growth rate of the market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the trachoma market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the trachoma market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment of trachoma will obstruct the growth rate of market. The low diagnosis rate and lack of healthcare infrastructure in developing economies will challenge the trachoma market. Additionally, a lack of awareness about the treatment and side effects linked with the medication will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This trachoma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the trachoma market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Trachoma causes blindness or vision impairment in around 1.9 million people worldwide, and it is still a public health issue in 44 countries. Trachoma is present in around 21 million persons around the world. The bulk of the victims are children around 3-6 years old. The disease is mostly found near the equator in dry, arid environments, with Sub-Saharan Africa having the most instances.

Trachoma market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Trachoma Market

Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery, while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of trachoma in recent months.

Global Trachoma Market Scope

The trachoma market is segmented on the basis of treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Medication
• Surgery
• Others

On the basis of treatment, the global trachoma market is segmented into medication and surgery. Medication can be further segmented into tetracycline, macrolides, ophthalmic anti-infective, sulfonamides, and others.

Route of Administration

• Oral
• Topical
• Others

The route of administration segment for the trachoma market is segmented into oral, topical and others.

 End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

On the basis of end-users, the trachoma market is segmented into hospitals, specialty clinics, homecare and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

On the basis of distribution channel, the trachoma market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.

Trachoma Market Regional Analysis/Insights

The Trachoma market is analysed and market size insights and trends are provided by country, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Trachoma market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Middle East and Africa dominates the trachoma market because of the growing prevalence of trachoma in this region. Additionally, growing focus of major key players will further propel the market’s growth rate in this region.

Asia-Pacific are expected to grow during the forecast period of 2022 to 2029 due to number of population and rising healthcare expenditure in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Trachoma Market Share Analysis

트라코마 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 있습니다. 위에 제공된 데이터 포인트는 트라코마 시장과 관련된 회사의 초점에만 관련이 있습니다.

트라코마 시장에서 활동하는 주요 기업은 다음과 같습니다.

• F. 호프만-라 로슈 유한회사(스위스)
• 마일런 NV(미국)
• Teva Pharmaceutical Industries Ltd.(예루살렘)
• 사노피(프랑스)
• 파이저 주식회사(미국)
• GlaxoSmithKline plc (영국)
• 노바티스 AG(스위스)
• Bayer AG(독일)
• 엘리 릴리 앤드 컴퍼니(미국)
• 머크앤코(미국)
• 알러간(아일랜드)
• 아스트라제네카(영국)
• AbbVie Inc.(미국)
• 존슨앤존슨 프라이빗 리미티드(미국)
• 시플라 주식회사(미국)  
• Bausch Health Companies Inc. (캐나다)
• 애벗(미국)
• Arbor Pharmaceuticals, Inc(미국)
• Apotex Inc. (캐나다)
• Fresenius Kabi AG(독일)

SKU-53150